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Abstract
Background: The regulation of growth and apoptosis in K562 cells by human bone marrow
mesenchymal stem cells (MSCs) from leukemia patients was investigated.
Methods:  K562 cells were cocultured with leukemic MSCs under serum deprivation. Cell
Counting Kit-8 (CCK-8), PI staining, Annexin V/PI binding and FACS assays were used to investigate
cell proliferation, cell cycle status, and apoptosis of K562 cells cultures in the presence or absence
of 10% serum. Western blotting was used to determine the levels of Akt, phosphorylated Akt (p-
Akt), the BCL-2 family member Bad, and phosphorylated Bad (p-Bad) proteins in K562 cells after
coculturing with MSCs. The effects of LY294002 (a specific inhibitor of PI3K) on protein expression
were also determined.
Results: K562 cell proliferation was inhibited by coculture with MSCs and the dominant cell cycle
was the G0-G1 phase. The proportion of apoptotic K562 cells was decreased and the levels of p-
Akt and p-Bad were upregulated after exposing K562 cells to MSCs. However, when LY294002
was used, p-Akt and p-Bad proteins inK562 cells showed a significant reduction, while no distinct
variation was seen in the nonphosphorylated Akt and Bad protein levels.
Conclusion: Leukemic MSCs can inhibit K562 cell expansion and modulate the cell cycle to a state
of relative quiescence. This allows the K562 cells to endure adverse conditions such as serum
starvation. The PI3K-Akt-Bad signaling pathway may be involved in this antiapoptotic process via
phosphorylation of the Akt and Bad proteins. Blocking MSC-induced transduction of the PI3K-Akt-
Bad pathway may be a potential strategy for a targeted therapy to combat leukemia.
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Introduction
Bone marrow is not only the source of leukemic cells, but
is also the primary site of leukemia relapse [1]. For these
reasons, the hematopoietic microenvironment (HM) of
the bone marrow plays a crucial role in the development
and progression of leukemia. Variations in the HM may
influence the biological behaviors of leukemia cells; for
example, induction of resistance to chemotherapy drugs
by hypoxia [2] is now known to involve many compo-
nents. One important HM component is the bone mar-
row mesenchymal stem cell (MSC), which is involved in
stabilizing microenvironments, and forming niches for
cancer cells to endure adverse conditions.
Investigators have demonstrated normal MSCs and estab-
lished MSC cell lines can protect leukemia cells from
apoptosis [3-5]. However, the role of leukemic MSCs in
the pathogenesis and prognosis of leukemia are still not
well elucidated. What is known is that a substantial
number of MSCs from leukemia patients are likely to dif-
ferentiate into malignant cells and it is these cells that play
multiple roles in directly regulating leukemia cells. How-
ever, the possibility that MSCs from patients with leuke-
mia possess similar ability to modulate leukemia cells has
not been well explored. Leukemic MSCs in all probability
will aid in cell survival under adverse conditions (e.g.,
hypoxia, chemotherapy, serum deprivation). For this rea-
son, we have designed a system that mimics a serum dep-
rivation condition (i.e., fetal bovine serum (FBS)
starvation) in order to observe the status of K562 cells and
the influence of leukemic MSCs upon them.
The PI3K-Akt signal pathway and its downstream target
BCL-2 family members play important roles in the induc-
tion and regulation of cell apoptosis, survival, prolifera-
tion and formation of the cellular framework [6]. Many
studies have shown that activation of this signaling path-
way in some leukemia cells continues for an extended
duration [7-9]. An uncertain relationship still exists
between the PI3K-Akt pathway and MSCs. Hence, the aim
of the present study was to provide a preliminary outline
of the variations of key proteins involved in the PI3K-AKt
signaling pathway in leukemia cells.
Materials and methods
Cell line
Human chronic myelogenous leukemia cell line K562 was
maintained in RPMI 1640 media supplemented with 10%
fetal bovine serum (FBS), 100 U/ml penicillin, 100 U/ml
streptomycin and 0.2 mmol/L glutamine at 37°C in a
humidified incubator with a 5% CO2 atmosphere. Prior to
the experiments, the K562 cells were suspended in com-
plete DF-12 medium (Gibco, containing 10% FBS, 100 U/
ml penicillin, 100 U/ml streptomycin and 0.2 mmol/L
glutamine) or in DF-12 medium without serum.
Isolation and characterization of human leukemic 
mesenchymal stem cells (MSCs)
Heparinized bone marrow from each patient (4 patients:
2 with chronic myelogenous leukemia in blast crisis, 1
with acute myelogenous leukemia, and 1 with acute lym-
phoblastic leukemia) was obtained after informed con-
sent. The marrow was diluted twice with phosphate
buffered saline (PBS), then isolated by Ficoll-Hypaque
(Institute of Hematology) density-gradient centrifugation.
Monocytes were collected by adherence to a plastic flask
and incubated for 48 hrs in MSC conditioned medium
containing 10% FBS, 0.2 mmol/L glutamine, 10-9 M Dex,
10 ng/ml EGF, 100 U/ml penicillin and 100 U/ml strepto-
mycin. Medium was replaced at least twice a week and
nonadherent cells were discarded. After 3-5 passages, the
cells met the minimal criteria for defining multipotent
mesenchymal stromal cells [10] with typical CD34-,
CD14-, HLA-DR-, CD73+, CD90+, and CD105+, as iden-
tified by flow cytometry (data not shown). Fluorescein
isothiocyanate labeled antibodies for the MSC immu-
nophenotype were purchased from BD Pharmingen,
except for CD105 antibody, which was phycoerythrin-
labeled and purchased from Serotec. When MSCs were
80%-90% confluent, they were digested with trypsin and
resuspended with MSC conditioning medium (supple-
mented with or without 10% serum) in preparation for
experiments.
Coculturing modifications for observing proliferation of 
K562 cells
Simple culture group (SCG group)
This group was divided into two subgroups based on cul-
ture media used. The SCG-N group represented the K562
cells cultured in completed DF-12 medium containing
10% FBS. The SCG-S group represented the K562 cells in
DF-12 medium without serum. Both subgroups were cul-
tured at 37°C in a humidified incubator with a 5% CO2
atmosphere for 72 hrs.
Contact culture group (CCG group)
MSCs were seeded into 24-well plates (Costar, Boden-
heim, Germany) at the initial density of 1 × 104 cells/well,
or 1 × 105 cells/well in 6-well plates (Costar, Bodenheim,
Germany), and maintained in a 5% CO2, humidified
atmosphere at 37°C for 24 hrs. The cells were then given
a total gamma-irradiation of 15 Gy. Subsequently, K562
were seeded at 105 cells/well and cocultured with MSCs in
24-well plates for 24, 48 or 72 hrs. The K562:MSC ratio
was 10:1, was selected according to previous litera-
ture[11]. The medium was supplemented with (CCG-N
group) or without (CCG-S group) 10% FBS.
Separately cocultured group (Transwell group)
MSCs (1 × 104 initial cell count) were cultured for 24 hrs
in the upper side of a transwell (NUNC Company, Den-Journal of Experimental & Clinical Cancer Research 2009, 28:141 http://www.jeccr.com/content/28/1/141
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mark) chamber partitioned by a polycarbonate mem-
brane (8.0 μm pore size, Corning Incorporated, Costar).
These MSCs were then given a total irradiation of 15 Gy.
After discarding the supernatant, the MSCs were cocul-
tured with 1 × 105 of K562 cells in the lower part in DF-12
medium (with or without 10% FBS) at 37°C, 5% CO2 for
72 hrs.
Preparation for the conditioned medium group
MSCs were cultured in complete DF-12 medium at 37°C,
5% CO2 for 72 hrs, then the culture medium was har-
vested and centrifuged at 2,000 rpm for 10 min and stored
at -80°C. This medium was doubled diluted with DF-12
medium without FBS then used to culture K562 cells for
72 hrs. The CM group included two subgroups cultured in
conditioned medium with or without FBS.
CCK-8 assay for detecting proliferation of K562 cells
Cells from the SCG, CCG, Transwell, and CM groups were
cultured in DF-12 media with or without FBS for further
observation. When cells were cocultured in different
media for 72 hrs, cell proliferation was measured with a
Cell Counting Kit-8 (Dojindo, Shanghai), following the
manufacturer's instructions.
Propidium iodide (PI) flow cytometric assay for 
determining cell cycle status under different nutritional 
states
The PI staining method was used for detecting the cell
cycle status of cells of the SCG-N, CCG-N and CCG-S
groups, using the manufacturer's protocol. Briefly, DNA
was stained with 50 μg/ml propidium iodide (Sigma).
Samples were kept for 1 hr in the dark at room tempera-
ture and the DNA index was then measured by cytofluor-
imetric analysis using an FACS Calibur flow cytometer
(Becton Dickinson, San Diego, CA). Data were analyzed
using CellQuest software.
Annexin V/PI for cell apoptotic analysis
Cell viability was detected by trypan blue and apoptosis
was evaluated by the annexin V/propidium iodide (BD
Biosciences) double staining assay following the manu-
facturer's instructions. K562 cells were harvested at the
end of treatment, rinsed twice with PBS, and stained with
Annexin V-FITC apoptosis detection kit I (BD Bio-
sciences). Analysis was performed on the FACS Calibur
using CellQuest software.
Western blotting
Three groups of K562 cells were cultured at 37°C, 5% CO2
for 24 hrs. SCG-S represented the group of K562 cells cul-
tured without FBS. CCG-S represented the group of K562
and MSCs without FBS. CCG-S+LY294002 represented
the group pretreated with 10 μM LY294002 for 1 hr. After
incubation, K562 cells were dissolved in lysis buffer (100
mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerin, 200 mM
dithiothreitol, plus protease inhibitors) and quantified
for proteins by a BCA protein assay kit (Pierce Company,
USA). Equal amounts of protein extract were loaded onto
a 12% SDS-PAGE gel and transferred to PVDF membrane
(Gibaino Company, Beijing, China). The blot was
blocked in 5% fat-free milk at 4°C overnight and then
incubated with mouse monoclonal anti-Akt, p-Akt-Ser-
473, anti-Bad, p-Bad-Ser-136 antibodies, (Cell Signal
Transduction). Mouse monoclonal anti-beta-actin anti-
body (Cell Signal Transduction) was used as control. The
immunocomplexes were visualized by using a chemilu-
minescent kit (Cell Signal Transduction).
Statistical analysis
Data were presented as mean ± SD, using the SPSS system
package for statistical analysis. Student-t-test was used for
comparison of two groups of data. One-Way ANOVA was
used for more than two groups of data. Multiple compar-
isons between two groups were analyzed by a SNK-q test.
A P value < 0.05 was considered significant.
Results
MSCs inhibit proliferation of K562 cells under different 
nutritional conditions
As shown in figure 1, the growth of K562 cells was clearly
decreased in the absence of serum in culture media. How-
ever, even with the addition of 10% FBS, viable cell num-
bers in the coculture, transwell, and CM experimental
MSCs inhibit the proliferation and viability of K562 cells Figure 1
MSCs inhibit the proliferation and viability of K562 
cells. Either in the present of MSCs or conditioned medium 
from MSCs, the suppression persisted signnificantly.Journal of Experimental & Clinical Cancer Research 2009, 28:141 http://www.jeccr.com/content/28/1/141
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groups were significantly decreased compared to the SCG
subgroups (p < 0.001). The CCG groups were especially
affected. This suggested that cell growth was inhibited
when K562 cells were cocultured with MSCs Moreover,
the suppression persisted even if the cells were separated
in a transwell system or were cocultured in MSC superna-
tant, which indicated the suppression effect was mediated
by some soluble substances, most likely cytokines.
Effects of MSCs on K562 cell cycles
As shown in figure. 2, when compared with SCG-N group,
the percentage of K562 cells in G0/G1 phase in the CCG-N
group was dramatically increased, with a concomitant
decrease in cells in the S phase. Moreover, with deficient
nutrition, the CCG-S group showed further increases in
the G0/G1 phase (39.60% vs. 51.30%) and reduction in
the S phase (47.98% vs. 33.93%). Although there may
have been an increased trend towards the G2-M phase, no
significance difference was observed among the three
groups. The presence of MSCs therefore reduced the num-
bers of leukemic cells in the S phase and increased the
number of cells in the G0-G1  phase. K562 cells were
arrested in the G0-G1 phase by the presence of MSCs. This
pattern was more obvious under serum deprivation (p =
0.007).
Effects of MSCs on the apoptosis of K562 cells
The Annexin V/PI assay was used to detect apoptosis in
K562 cells. As shown in figure 3, following FBS starvation
for 24 hrs, the proportion of apoptotic K562 cells was sig-
nificantly increased compared to that in groups supple-
mented with 10% FBS. After coculturing with MSCs, cell
apoptosis was significantly decreased compared with
SCG-S (p = 0.011), yielding results similar to those of the
SCG-N group. However, in the presence of LY294002, the
magnitude of the decrease in apoptosis was reduced
(5.09% vs. 7.15%). As LY294002 is a the specific inhibitor
of PI3K, the antiapoptotic ability of MSCs might have
Cell cycle distribution of K562 cells in SCG-N (A), CCG-N (B) and CCG-S (C) groups Figure 2
Cell cycle distribution of K562 cells in SCG-N (A), CCG-N (B) and CCG-S (C) groups. K562 cells were arrested in 
the G0-G1 phase by the presence of MSCs.Journal of Experimental & Clinical Cancer Research 2009, 28:141 http://www.jeccr.com/content/28/1/141
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some relationship with the P13K signal pathway. Thus, we
next examined the levels of known antiapoptotic proteins
in K562 cells.
Effects of MSCs on protein expression in K562 cells
Western blotting showed that the presence of MSCs raised
the levels of the PI3K-Akt-related antiapoptotic proteins,
p-Akt and p-Bad, in K562 cells. As shown in figure 4A, the
60KD band of Akt showed no significant difference
among the SCG-S, CCG-S, CCG-S+LY294002 groups. In
contrast, for the phosphorylated form p-Akt, expression
levels were clearly higher in CCG-S group. Addition of
LY294002 resulted in a reversal, with p-Akt level being
similiar to that of the SCG-S group. These data indicate
that the phosphorylation of Akt is apparently involved in
the antiapoptotic process mediated by MSCs.
As shown in figure 4B, a band at 23 KD, representing the
Bad and p-Bad proteins in K562 cells, also showed obvi-
ous increases in the phosphorylated form of Bad in the
CCG-S group. Upregulation was nearly reversed by treat-
ment with LY294002, which causes an upstream blockade
of PI3K. There were no significant variations among the
Bad levels of these groups.
Discussion
As evidence on bone marrow HM has accumulated over
the past few years, it has become widely acknowledged
that MSCs affect a great number of different cell types
besides hematopoietic parenchymal cells, including
leukemia cells [11-13]. With this close relationship
between MSCs and leukemia cells, it may be that the influ-
ence of MSCs is what ultimately determines the prognosis
of leukemia.
In general, MSCs in the HM have been considered to be
nurse-like cells that exert a form of protective modulation.
Leukemic MSCs can reportedly inhibit the chemothera-
peutic-induced apoptosis of Jurkat cells and HL-60 cells.
Moreover, they can interfere with the cell cycle of Jurkat
cells at the G0-G1 phase [14,15]. They can also negatively
regulate cancer immunotherapy involving NK cells and
inhibit cytotoxic T cells by secreting cytokines [16,17].
Thus, there appear to be multiple roles of MSCs in prolif-
eration, differentiation, and survival of leukemia cells [18-
20] as well as normal immune cells. In the present study,
the role of leukemic MSCs on K562 cells was explored
under normal nutritional conditions or under serum star-
vation. We noticed a marked increase in K562 cell apop-
tosis after serum starvation for 24 hours. However, a
marked decrease in apoptosis was observed when these
Apoptotic percentages of K562 cells cultivated in different media Figure 3
Apoptotic percentages of K562 cells cultivated in different media. (A), SCG-N, K562 cells cultivated in DF-12 with 
10%FBS. (B), SCG-S, K562 cells cultivated without FBS. (C), K562 cells in CCG-S+MSCs+LY294002 group were pretreated 
with 10 μM LY294002 for 1 hr then cocultured with MSCs in DF-12 media without FBS. (D), CCG-S+MSCs, K562 cells culti-
vated with MSCs in the present of FBS-free medium.Journal of Experimental & Clinical Cancer Research 2009, 28:141 http://www.jeccr.com/content/28/1/141
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starved cells were cocultured with MSCs, supporting the
protective role of leukemic MSCs against apoptosis. This
inhibition existed both in contact coculture and in sepa-
rated coculture, and was induced even by supernatant cul-
ture medium from MSCs. Thus, our data support that
cytokines, adherent reactions and gap junctions partici-
pated in inhibiting leukemic cell proliferation.
When K562 cells were cocultured with normal MSCs, they
also showed cell cycle blockade. These K562 cells also
showed drug-resistance to daunorubicin (DNR), which is
consistent with their increased G0-G1 phase and reduced S
phase. The reasons for this drug resistance may also relate
to the upregulation of antiapoptotic gene expression and
the cytokines secreted by MSCs. Our data also showed a
similar cell cycle blockade of K562 cells resulting from
coculture with leukemic MSCs obtained from 4 patients,
although these nurse cells may have undergone malignant
transformation in vivo or over their long time in culture.
Inhibition of cell growth is a primary method of treating
leukemia; however, the blockade of the cell cycle may pre-
vent the efficacy of chemotherapeutic agents, which
mainly target the proliferative phase of tumor cells. When
most tumor cells are blocked at the quiescent phase, they
may evade the killing powers of chemotherapeutics and
may ultimately form micro residual disease (MRD). We
hypothesize that leukemic MSCs may provide a niche for
tumor stem cells, in which K562 cells back up the prolif-
eration and self-renewal potential. These tumor cells may
then be the source of relapse.
Constitutive activation of Akt, one downstream target of
PI3K, is also believed to promote proliferation and
increase cell survival, leading to cancer progression[21].
The PI3K-Akt signal pathway is involved in the antiapop-
totic activity of tumor cells and culminates in the phos-
phorylation of the BCL-2 family member, Bad, thereby
suppressing apoptosis and promoting cell survival. Akt
phosphorylates Bad both in vitro and in vivo, and blocks
Bad-induced cell death [22]. The PI3K-Akt-Bad pathway
may represent a form of general antiapoptotic machinery,
although there is insufficient evidence to support this
hypothesis at present.
We determined the expression levels of Akt, p-Akt, Bad, p-
Bad proteins in K562 cells after inoculation with MSCs.
Under the condition of K562 cells alone, there was a basal
expression of p-Akt, and p-Bad, which might have been
related to the bcr/abl fusion protein-activated PI3K-Akt
signal pathway. In addition, the expression of p-Akt and
p-Bad was increased after coculture with leukemic MSCs.
The addition of the specific inhibitor LY294002, which
competes with PI3K for ATP binding sites [23], resulted in
a dramatic decrease in levels of both phosphorylated pro-
teins, while no obvious difference in Akt and Bad expres-
sion was observed among the three groups. Hence, we
showed that the PI3K-Akt pathway was activated after coc-
ulture with MSCs. The pro-apoptotic molecule, Bad, was
then phosphorylated and exerted inhibitory effects on
starvation-induced apoptosis.
Taken together, serum deprivation appears to mimic the
effects of an adverse HM for leukemia cells. MSCs of
leukemia patients can retard the cell cycles of K562 cells,
inhibiting their proliferation and reducing their apopto-
sis. Consequently, MSCs protect leukemia cells against
adverse conditions like serum deprivation and ultimately
sustain their viability. The activation of the PI3K-Akt-Bad
signaling pathway seems to be involved in the protective
machinery. Therefore, approaches that block the activa-
tion of this signaling pathway may in turn remove this
shielding and consequently may prove to be of benefit in
the effective treatment of leukemia.
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